1155270-71-5

Basic information

• Product Name: 7-bromo-5-chloro-2,3-dihydropyrano[4,3,2-de]quinoline
• CAS NO: 1155270-71-5
• Molecular Weight: 284.54
• Mol File: 1155270-71-5.mol

Chemical Properties

• CAS DataBase Reference: 7-bromo-5-chloro-2,3-dihydropyrano[4,3,2-de]quinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 7-bromo-5-chloro-2,3-dihydropyrano[4,3,2-de]quinoline(1155270-71-5)
• EPA Substance Registry System: 7-bromo-5-chloro-2,3-dihydropyrano[4,3,2-de]quinoline(1155270-71-5)

Safety Data

• Hazardous Substances Data: 1155270-71-5(Hazardous Substances Data)

Upstream product

• 1155270-69-1 8-bromo-5-hydroxy-4-(2-hydroxyethyl)quinolin-2(1H)-one 
• 197243-48-4 2-iodo-3-nitrophenol 
• 1155270-68-0 8-bromo-4-(2-hydroxyethyl)-5-methoxyquinolin-2(1H)-one 
• 1155270-67-9 2-(8-bromo-5-methoxy-2-oxo-1,2-dihydroquinolin-4-yl)acetic acid 
• 1155270-66-8 C₁₄H₁₄BrNO₆ 
• 59557-92-5 2-bromo-5-methoxyaniline 
• 5344-78-5 4-bromo-3-nitroanizole 
• 100367-37-1 3-amino-4-bromophenol 
• 1402597-31-2 methyl 2-(8-bromo-5-hydroxy-2-oxo-1,2-dihydroquinolin-4-yl)acetate 
• 15997-62-3 2,6-dioxo-3,6-dihydro-2H-pyran-4-yl acetate 
• 542-05-2 acetonedicarboxylic acid 

Downstream Products

• 1155270-72-6 7-bromo-2,3-dihydropyrano[4,3,2-de]quinoline 
• 1402714-51-5 C₂₈H₂₈N₂O₄ 
• 1155419-89-8 BI-224436 
• 1402714-51-5 methyl 2-(tert-butoxy)-2-((R)-4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetate 
• 1402714-51-5 methyl 2-(tert-butoxy)-2-((S)-4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetate 
• 1155419-89-8 2-(tert-butoxy)-2-((R)-4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid 

Relevant articles and documents

A palladium-catalyzed intramolecular carbonylative annulation reaction for the synthesis of 4,5-fused tricyclic 2-quinolones

A concise and efficient synthetic route to 4,5-fused tricyclic 2-quinolones through the palladium-catalyzed carbonylative annulation of alkyne-tethered N-substituted o-iodoanilines has been developed. This reaction proceeds smoothly under mild reaction conditions and exhibits exceptional tolerance to a variety of functional groups. It has been successfully applied to the efficient synthesis of BI 224436, an HIV integrase inhibitor.

Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor

Abstract A practical and efficient synthesis of a complex chiral atropisomeric HIV integrase inhibitor has been accomplished. The combination of a copper-catalyzed acylation along with the implementation of the BI-DIME ligands for a ligand-controlled Suzuki cross-coupling and an unprecedented bis(trifluoromethane)sulfonamide-catalyzed tert-butylation renders the synthesis of this complex molecule robust, safe, and economical. Furthermore, the overall synthesis was conducted in an asymmetric and diastereoselective fashion with respect to the imbedded atropisomer. Atropselective: An efficient asymmetric synthesis of an atropisomeric HIV inhibitor has been accomplished. The combination of a copper-catalyzed acylation with the implementation of BI-DIME ligands for a ligand-controlled Suzuki cross-coupling and an unprecedented bis(trifluoromethane)sulfonamide-catalyzed tert-butylation renders the synthesis of this complex molecule robust, safe, and economical.

PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR

The present invention is directed to an improved process for the preparation of Compounds of Formula (I) or salts thereof which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)- 2-methylquinolin-3-yl)acetic acid or salt thereof which is useful in the treatment of HIV infection. R4 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n) and (o); and R6 and R7 are each independently selected from H, halo and (C1-6) alkyl.

THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS

The present invention relates to a series of compounds of formula (A) having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.